Rationally designed small molecules that target both the DNA and RNA causing myotonic dystrophy type 1

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Myotonic dystrophy type 1 (DM1) pathogenesis involves toxic CTG repeat expansions in the DMPK gene.
• The expanded CUG transcript (CUG(exp)) sequesters proteins like MBNL, undergoes RAN translation, and dysregulates microRNAs.

Purpose of the Study:

• To design and evaluate rationally designed, multi-target small molecules for DM1 therapy.
• To address the complex pathobiology of DM1 through simultaneous targeting of key molecular events.

Main Methods:

• Development of small molecules with three distinct mechanisms of action: transcription inhibition, inhibition of aberrant RNA-protein binding, and RNA degradation.
• In vitro assessment of agent binding to CTG(exp), inhibition of MBNL1 sequestration, and RNase-like cleavage activity.
• Evaluation of lead compounds in DM1 model cells and a DM1 Drosophila model for efficacy in reducing CUG(exp) and reversing phenotypes.

Main Results:

• Agents demonstrated in vitro ability to bind CTG(exp), inhibit its formation, prevent MBNL1 sequestration, and cleave the toxic RNA.
• Potent compounds successfully reduced CUG(exp) levels in DM1 model cells.
• One compound reversed two distinct CUG(exp)-induced phenotypes in a DM1 Drosophila model.

Conclusions:

• Rationally designed multi-target agents show significant therapeutic potential for DM1.
• These agents effectively address key molecular defects underlying DM1 pathobiology.
• Further development of these compounds could lead to novel treatments for DM1.